---
figid: PMC7763629__pharmaceutics-12-01198-g002
figtitle: RTKs (EGFR) signal transduction and are a target site for small molecule
  and monoclonal antibody in glioma treatment
organisms:
- NA
pmcid: PMC7763629
filename: pharmaceutics-12-01198-g002.jpg
figlink: pmc/articles/PMC7763629/figure/pharmaceutics-12-01198-f002/
number: F2
caption: RTKs (EGFR) signal transduction and are a target site for small molecule
  and monoclonal antibody in glioma treatment. Small-molecule tyrosine kinase inhibitors
  block the downstream signaling by competing for ATP at the catalytic site of the
  kinase domain whilst the monoclonal antibodies (mAbs), which have an outstanding
  degree of specificity, block downstream signaling by binding to the leucine-rich
  and cysteine-rich ectodomains. Compounds that inhibit mammalian target of rapamycin
  (mTOR), a downstream signal in the EGFR pathway, facilitate the autophagic clearance
  of cancerous cells.
papertitle: Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma
  Management.
reftext: Sathishbabu Paranthaman, et al. Pharmaceutics. 2020 Dec;12(12):1198.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9649723
figid_alias: PMC7763629__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC7763629__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7763629__pharmaceutics-12-01198-g002.html
  '@type': Dataset
  description: RTKs (EGFR) signal transduction and are a target site for small molecule
    and monoclonal antibody in glioma treatment. Small-molecule tyrosine kinase inhibitors
    block the downstream signaling by competing for ATP at the catalytic site of the
    kinase domain whilst the monoclonal antibodies (mAbs), which have an outstanding
    degree of specificity, block downstream signaling by binding to the leucine-rich
    and cysteine-rich ectodomains. Compounds that inhibit mammalian target of rapamycin
    (mTOR), a downstream signal in the EGFR pathway, facilitate the autophagic clearance
    of cancerous cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - gfr
  - nac
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - MKP-4
  - p38b
  - rl
  - Erk7
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Mtor
  - Tor
  - grb
  - Sos
  - Pten
  - Pdk1
  - Dsor1
  - RAPGEF5
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - XYLT2
  - SOS1
  - SOS2
  - PTEN
  - BRAF
  - PDK1
  - PDPK1
  - MAP2K1
  - MAP2K2
  - tyrosine
  - Erlotinib
  - Gefitinib
  - Vandetanib
  - Lapatinib
  - Sirolimus
  - Temsirolimus
  - Everolimus
  - Glioma
---
